Atea Pharmaceuticals (NASDAQ:AVIR) PT Lowered to $8.00

Atea Pharmaceuticals (NASDAQ:AVIR – Get Rating) had its price target reduced by equities research analysts at JPMorgan Chase & Co. from $12.00 to $8.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 112.20% from […]

Related Keywords

,Morgan Stanley ,Atea Pharmaceuticals Company Profile ,Blackrock Inc ,Renaissance Technologies ,Hedge Funds Weigh In On Atea Pharmaceuticals ,Vanguard Group Inc ,News Ratings For Atea Pharmaceuticals Daily ,Atea Pharmaceuticals ,Jpmorgan Chase Co ,Atea Pharmaceuticals Stock Performance ,Atea Pharmaceuticals Inc ,Hermes Inc ,Get Rating ,Atea Pharmaceuticals Daily ,Nasdaq Avir ,Tavir ,Medical ,Lower Price Target ,